OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial	91
CAR T-cell therapy comes of age: Introductory editorial for the special issue	61
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	56
Clinical applications of circulating tumor DNA in Hodgkin lymphoma	51
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia	49
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies	48
How to set up a clinical research center in Brazil, as an example of a middle-income country	41
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19	29
Updates on current and future research in acute myeloid leukemia	25
Epidemiology and etiology of diffuse large B-cell lymphoma	24
Lessons learned from the Eµ-TCL1 mouse model of CLL	22
Somatic mutations in “benign” blood diseases	21
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services	20
The role of viruses in HIV-associated lymphomas	20
TET2 mutation as prototypic clonal hematopoiesis lesion	19
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence	19
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future	17
Antibody and immunotherapy in diffuse large B-cell lymphoma	17
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?	16
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors	16
Vaccinations in patients with chronic lymphocytic leukemia	14
The molecular map of CLL and Richter's syndrome	14
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients	13
T-cell engaging antibodies for B-cell lymphomas	13
Clonal hematopoiesis	13

At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics	13
Tribute to an editor: Neal S. Young As a Medical Editor and Writer	13
outside front cover, PMS 8883 metallic AND 4/C	12
Cellular and immunotherapies for myelodysplastic syndromes	12
outside front cover, PMS 8883 metallic AND 4/C	12
outside front cover, PMS 8883 metallic AND 4/C	11
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations	11
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	10
Aplastic anemia: Quo vadis?	9
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy	9
Challenges and opportunities of CAR T-cell therapies for CLL	9
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	9
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead	9
The biology of classical Hodgkin lymphoma	9
Understanding MDS stem cells: Advances and limitations	8
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS	8
Somatic mutations in acquired pure red cell aplasia	8
Menin inhibition for the treatment of acute leukemia	8
Harnessing single-domain antibodies for CAR-T and bispecific antibody development	8
Somatic compensation of inherited bone marrow failure	8
The pediatric approach to Hodgkin lymphoma	8
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)	8
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome	7
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials	7
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia	7
DLBCL arising from indolent lymphomas: How are they different?	7
The crossroads of cancer therapies and clonal hematopoiesis	7
Clinical applications of circulating tumor DNA in central nervous system lymphoma	7
The emergence of a new paradigm with signal 1 and signal 2 T-cell engagers in hematology	7
Measurable residual disease after CAR T-cell therapy	6
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	6
Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress	6
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies	6
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease	6
outside front cover, PMS 8883 metallic AND 4/C	6
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	6
outside front cover, PMS 8883 metallic AND 4/C	6
miRNA Biology in Chronic Lymphocytic Leukemia	6
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	6
License for a CAR T: Examining patient eligibility	6
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters	6
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	5
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	5
RNA splicing as a therapeutic target in myelodysplastic syndromes	5
Platelet-activating anti-PF4 disorders: An overview	5
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	5
Updates on the biology of chronic lymphocytic leukemia: introductory editorial	5
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	5
AML diagnostics in the 21st century: Use of AI	5
Special edition of the Seminars in Hematology series on Global Hematology Care	5

Clonal hematopoiesis in the setting of hematopoietic cell transplantation	5
Collaborations, colleagues, and friendships: The Hematology Branch and blood disease centers in Asia	5
Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications	5
Inflammation in myelodysplastic syndrome pathogenesis	5
Applications of virus-specific T cell therapies post-BMT	4
Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers	4
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes	4
The case for prioritizing malignant hematology services in low- and middle-income countries	4
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL	4
Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma	4
Special issue on circulating tumor DNA: Introductory editorial	4
Role of the tumor microenvironment in CLL pathogenesis	4
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?	4
The Management of older patients with Hodgkin lymphoma: implications of S1826	4
Tuning CAR T-cell therapies for efficacy and reduced toxicity	4
Resolving leukemic stem cell heterogeneity and plasticity with single-cell multiomics	3
Immunosuppressive therapy in severe aplastic anemia	3
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)	3
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors	3
Tailoring intensive and less-intensive treatment in acute myeloid leukemia	3
outside front cover, PMS 8883 metallic AND 4/C	3
Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories	3
outside front cover, PMS 8883 metallic AND 4/C	3
Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach	3
The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies	3
masthead	3
BCMA biology and therapeutic targeting in multiple myeloma: from ligand signaling to antigen escape	3
Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes	3
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence	3